NASDAQ:ZYNE Zynerba Pharmaceuticals - ZYNE Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zynerba Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.42 -0.02 (-4.53%) (As of 03/30/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.41▼$0.4450-Day Range$0.40▼$0.6752-Week Range$0.39▼$2.28Volume59,198 shsAverage Volume271,035 shsMarket Capitalization$19.28 millionP/E RatioN/ADividend YieldN/APrice Target$11.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Zynerba Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside2,510.3% Upside$11.00 Price TargetShort InterestHealthy0.52% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.69Based on 8 Articles This WeekInsider TradingSelling Shares$54,328 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.66) to ($0.63) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.20 out of 5 starsMedical Sector389th out of 1,009 stocksPharmaceutical Preparations Industry176th out of 494 stocks 3.3 Analyst's Opinion Consensus RatingZynerba Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.00, Zynerba Pharmaceuticals has a forecasted upside of 2,510.3% from its current price of $0.42.Amount of Analyst CoverageZynerba Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.52% of the outstanding shares of Zynerba Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverZynerba Pharmaceuticals has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Zynerba Pharmaceuticals has recently increased by 30.84%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldZynerba Pharmaceuticals does not currently pay a dividend.Dividend GrowthZynerba Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ZYNE. Previous Next 2.6 News and Social Media Coverage News SentimentZynerba Pharmaceuticals has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Zynerba Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 6 people have searched for ZYNE on MarketBeat in the last 30 days. This is a decrease of -45% compared to the previous 30 days.MarketBeat Follows3 people have added Zynerba Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Zynerba Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $54,328.00 in company stock.Percentage Held by Insiders10.54% of the stock of Zynerba Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 23.82% of the stock of Zynerba Pharmaceuticals is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Zynerba Pharmaceuticals are expected to grow in the coming year, from ($0.66) to ($0.63) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zynerba Pharmaceuticals is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Zynerba Pharmaceuticals is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioZynerba Pharmaceuticals has a P/B Ratio of 0.25. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Zynerba Pharmaceuticals (NASDAQ:ZYNE) StockZynerba Pharmaceuticals, Inc. engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. It focuses on the research and development of rare and near-rare neuropsychiatric conditions. The firm offers the Zygel product, which is formulated as a permeation-enhanced gel for transdermal delivery. The company was founded by Audra L. Stinchcomb on January 31, 2007 and is headquartered in Devon, PA.Read More Receive ZYNE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zynerba Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ZYNE Stock News HeadlinesMarch 30, 2023 | americanbankingnews.comZynerba Pharmaceuticals (NASDAQ:ZYNE) Posts Quarterly Earnings Results, Beats Expectations By $0.06 EPSMarch 30, 2023 | americanbankingnews.comZynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Short Interest UpdateMarch 31, 2023 | WealthPop (Ad)Here’s Your Own Billion-Dollar Trading Edge (Just $0.76 a Week)2023 is a classic “stock picker’s market.” The only way to beat these markets is to pick the right stocks at the right time. Legendary trader Adam Mesh is ready to hand you his best stock pick every week… It’s the same kind of research Wall Street’s top traders use to beat the markets. Click here to get his three top picks for right now to help get you started now. March 29, 2023 | americanbankingnews.comZynerba Pharmaceuticals (NASDAQ:ZYNE) Now Covered by Analysts at StockNews.comMarch 28, 2023 | finanznachrichten.deZynerba Pharmaceuticals, Inc.: Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational HighlightsMarch 28, 2023 | benzinga.comZynerba Pharmaceuticals R&D Expenses For FY22 Reach $21.1M, What About Net Loss?March 28, 2023 | finance.yahoo.comZynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational HighlightsMarch 21, 2023 | americanbankingnews.comStockNews.com Initiates Coverage on Zynerba Pharmaceuticals (NASDAQ:ZYNE)March 31, 2023 | WealthPop (Ad)Here’s Your Own Billion-Dollar Trading Edge (Just $0.76 a Week)2023 is a classic “stock picker’s market.” The only way to beat these markets is to pick the right stocks at the right time. Legendary trader Adam Mesh is ready to hand you his best stock pick every week… It’s the same kind of research Wall Street’s top traders use to beat the markets. Click here to get his three top picks for right now to help get you started now. March 14, 2023 | finanznachrichten.deZynerba Pharmaceuticals, Inc.: Zynerba Pharmaceuticals Confirms Not Holding Cash Deposits or Securities at Silicon Valley BankMarch 13, 2023 | finance.yahoo.comZynerba Pharmaceuticals Confirms Not Holding Cash Deposits or Securities at Silicon Valley BankMarch 7, 2023 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: BioMarin Pharmaceutical (BMRN) and Armata Pharmaceuticals (ARMP)March 7, 2023 | finance.yahoo.comZynerba Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare ConferenceMarch 1, 2023 | finance.yahoo.comZynerba Pharmaceuticals to Present at the Cowen 43rd Annual Health Care ConferenceFebruary 21, 2023 | marketwatch.comFibromyalgia Treatment Drug Market Outlook 2023 and Forecast to 2028 with Top Countries DataFebruary 13, 2023 | marketwatch.com2023, Pain Management Drugs Market to Experience a Significant Increase in Revenues by 2027January 27, 2023 | marketwatch.comFibromyalgia Treatment Drug Market 2023 : Profiling Key Players, Value Estimation and Analysis by Recent Trends to 2028January 12, 2023 | msn.comWhat's The Role Of The Endocannabinoid System In Fragile X Syndrome? How Can Cannabidiol Treatment Help? New PaperJanuary 11, 2023 | finance.yahoo.comZynerba Pharmaceuticals Announces Publication in the Journal of Neurodevelopmental Disorders Describing the Role of the Endocannabinoid System and Cannabidiol Therapy in Fragile X SyndromeJanuary 10, 2023 | forbes.comZynerba PharmaceuticalsDecember 21, 2022 | proactiveinvestors.comZynerba Pharmaceuticals revises timeline for release of topline results from Phase 3 RECONNECT trial of Zygel in Fragile X syndromeDecember 21, 2022 | finance.yahoo.comZynerba Pharmaceuticals delays data on genetic disorder drug studyDecember 21, 2022 | finance.yahoo.comZynerba Pharmaceuticals Announces Update on RECONNECT, the Pivotal Phase 3 Trial of Zygel™ in Fragile X SyndromeDecember 21, 2022 | finance.yahoo.comUPDATE 2-Zynerba delays genetic disorder drug data on enrollment challengeDecember 5, 2022 | msn.comCBD-Based Zygel Helps With Anxiety-Related & Behavioral Symptoms In 22q11.2 Deletion Syndrome, Phase 2 Trial RevealsDecember 5, 2022 | finance.yahoo.comZynerba Pharmaceuticals Announces Positive Long-Term Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at the Annual Meeting of the American College of NeuropsychopharmacologyNovember 29, 2022 | finance.yahoo.comZynerba Pharmaceuticals Announces Poster Presentation at the Annual Meeting of the American College of NeuropsychopharmacologySee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ZYNE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zynerba Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ZYNE Company Calendar Last Earnings3/28/2023Today3/31/2023Next Earnings (Estimated)5/15/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ZYNE CUSIPN/A CIK1621443 Webwww.zynerba.com Phone(484) 581-7505FaxN/AEmployees28Year FoundedN/APrice Target and Rating Average Stock Price Forecast$11.00 High Stock Price Forecast$11.00 Low Stock Price Forecast$11.00 Forecasted Upside/Downside+2,510.3%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.87) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,310,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-58.25% Return on Assets-50.31% Debt Debt-to-Equity RatioN/A Current Ratio6.45 Quick Ratio6.45 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.72 per share Price / Book0.25Miscellaneous Outstanding Shares45,750,000Free Float40,931,000Market Cap$19.28 million OptionableOptionable Beta1.74 Key ExecutivesArmando AnidoChairman & Chief Executive OfficerTerri B. SebreePresidentJames E. FickenscherChief Financial Officer & VP-Corporate DevelopmentNancy TichVice President-ClinicalCarol B. O'NeillVice President-DevelopmentKey CompetitorsVincerx PharmaNASDAQ:VINCForte BiosciencesNASDAQ:FBRXCelyad OncologyNASDAQ:CYADComera Life SciencesNASDAQ:CMRAEdesa BiotechNASDAQ:EDSAView All CompetitorsInsiders & InstitutionsETF Managers Group LLCSold 748,098 shares on 3/23/2023Ownership: 3.302%Millennium Management LLCSold 37,462 shares on 2/15/2023Ownership: 1.224%Two Sigma Investments LPSold 51,592 shares on 2/14/2023Ownership: 0.155%Geode Capital Management LLCSold 25,055 shares on 2/13/2023Ownership: 0.847%Wells Fargo & Company MNSold 30,714 shares on 2/13/2023Ownership: 0.127%View All Insider TransactionsView All Institutional Transactions ZYNE Stock - Frequently Asked Questions Should I buy or sell Zynerba Pharmaceuticals stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zynerba Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ZYNE shares. View ZYNE analyst ratings or view top-rated stocks. What is Zynerba Pharmaceuticals' stock price forecast for 2023? 3 analysts have issued 1-year price targets for Zynerba Pharmaceuticals' shares. Their ZYNE share price forecasts range from $11.00 to $11.00. On average, they predict the company's stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 2,510.3% from the stock's current price. View analysts price targets for ZYNE or view top-rated stocks among Wall Street analysts. How have ZYNE shares performed in 2023? Zynerba Pharmaceuticals' stock was trading at $0.53 at the start of the year. Since then, ZYNE shares have decreased by 20.5% and is now trading at $0.4214. View the best growth stocks for 2023 here. Are investors shorting Zynerba Pharmaceuticals? Zynerba Pharmaceuticals saw a increase in short interest in March. As of March 15th, there was short interest totaling 238,000 shares, an increase of 30.8% from the February 28th total of 181,900 shares. Based on an average trading volume of 327,300 shares, the short-interest ratio is presently 0.7 days. View Zynerba Pharmaceuticals' Short Interest. When is Zynerba Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 15th 2023. View our ZYNE earnings forecast. How were Zynerba Pharmaceuticals' earnings last quarter? Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) announced its earnings results on Tuesday, March, 28th. The company reported ($0.18) earnings per share for the quarter, topping analysts' consensus estimates of ($0.24) by $0.06. What ETFs hold Zynerba Pharmaceuticals' stock? ETFs with the largest weight of Zynerba Pharmaceuticals (NASDAQ:ZYNE) stock in their portfolio include Amplify Seymour Cannabis ETF (CNBS).ETFMG Alternative Harvest ETF (MJ). What other stocks do shareholders of Zynerba Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Zynerba Pharmaceuticals investors own include Cara Therapeutics (CARA), GW Pharmaceuticals (GWPH), Cronos Group (CRON), Aurora Cannabis (ACB), NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Shopify (SHOP) and Micron Technology (MU). When did Zynerba Pharmaceuticals IPO? (ZYNE) raised $42 million in an initial public offering on Wednesday, August 5th 2015. The company issued 3,000,000 shares at a price of $13.00-$15.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity and Oppenheimer & Co. were co-managers. What is Zynerba Pharmaceuticals' stock symbol? Zynerba Pharmaceuticals trades on the NASDAQ under the ticker symbol "ZYNE." Who are Zynerba Pharmaceuticals' major shareholders? Zynerba Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include ETF Managers Group LLC (3.30%), Renaissance Technologies LLC (1.84%), Millennium Management LLC (1.22%), Geode Capital Management LLC (0.85%), Two Sigma Investments LP (0.16%) and Wells Fargo & Company MN (0.13%). Insiders that own company stock include Armando Anido, Brian Rosenberger, Daniel L Kisner, James E Fickenscher and Terri B Sebree. View institutional ownership trends. How do I buy shares of Zynerba Pharmaceuticals? Shares of ZYNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Zynerba Pharmaceuticals' stock price today? One share of ZYNE stock can currently be purchased for approximately $0.42. How much money does Zynerba Pharmaceuticals make? Zynerba Pharmaceuticals (NASDAQ:ZYNE) has a market capitalization of $19.28 million. The company earns $-37,310,000.00 in net income (profit) each year or ($0.87) on an earnings per share basis. How can I contact Zynerba Pharmaceuticals? Zynerba Pharmaceuticals' mailing address is 80 W. LANCASTER AVENUE SUITE 300, DEVON PA, 19333. The official website for the company is www.zynerba.com. The company can be reached via phone at (484) 581-7505 or via email at investorrelations@zynerba.com. This page (NASDAQ:ZYNE) was last updated on 3/31/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.